GlassScriptPhysician profile
Stephen Markewich
NPI 1295959823
$56,725.50
in general payments reported to CMS, 2019-2025
27 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $1,483 · 2021: $1,404 · 2022: $1,338 · 2023: $2,605 · 2024: $2,037 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253 · Travel and Lodging: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.59 |
| Travel and Lodging | $1,759.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $47,534.73 | 2019-2020 | |
| Boston Scientific Corporation | $2,876.20 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Nevro Corp. | $1,508.11 | 2020-2024 | Senza |
| Stryker Corporation | $1,315.40 | 2024 | Augment Injectable |
| Relievant Medsystems, INC. | $1,274.58 | 2023 | Intracept |
| Abbvie INC. | $415.53 | 2021-2025 | |
| Medtronic, INC. | $304.51 | 2021-2025 | Synchromedii, Accurian |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.28 | 2022-2024 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $204.80 | 2022 | |
| Nutech Spine, INC. | $202.86 | 2021 | |
| Vertos Medical, INC. | $187.46 | 2023-2024 | Mild Device Kit |
| Pfizer INC. | $108.11 | 2023-2024 | |
| Amgen INC. | $79.64 | 2019 | |
| Abbott Laboratories | $64.25 | 2021-2023 | Proclaim |
| Allergan, INC. | $61.86 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $45.34 | 2023-2024 | Belbuca, Xtampza |
| Arbor Pharmaceuticals, INC. | $41.09 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $39.18 | 2025 | |
| Depuy Synthes Sales INC. | $34.40 | 2024 | Monovisc |
| Biodelivery Sciences International, INC. | $27.31 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $26.31 | 2023 | Zilretta |
| Averitas Pharma INC. | $22.72 | 2024 | Qutenza |
| Azurity Pharmaceuticals, INC. | $20.65 | 2023 | Horizant |
| Painteq LLC | $19.54 | 2024 | Painteq |
| Grt US Holding, INC. | $16.43 | 2022 | |
| Si-Bone, INC. | $14.90 | 2024 | |
| Merck Sharp & Dohme LLC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Markewich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.